Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia And Metabolic Syndrome
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2010, Vol 17, Issue 4
Abstract
Introduction and Objective: The aim of this study was to evaluate the relationship between lower urinary tract symptoms (LUTS), benign prostatic hyperplasia, and metabolic syndrome. Methods: 381 patients, over 45 years, with metabolic syndrome were divided in 2 groups: group A – 310 patients with BHP (MetS+BPH) and, group B – 71 patients without BPH (MetS-BPH). Fasting concentrations of plasma glucose, HbA1c, serum lipides (total cholesterol, triglycerides, high-density lipoprotein HDL-C), insulin, and prostate-specific antigen (PSA) were measured under standardised conditions at baseline, 6 months and one year. IR (insulin resistance) was determinated using homeostasis model assessment (HOMA-IR). The presence of LUTS was assessed using the International Prostate Symptoms Score. The prostate gland volume was measured using transrectal ultrasound (prostate volume over 30 cm3 was considered prostatic hyperplasia). Results: Prevalence of severe LUTS was 14.8% (n=46) in BPH patients and 4.2% (n=3) patients without prostatic diseases (0.032). Prevalence of moderate LUTS was 74.2% (n=230) in BPH patients and 78.9% (n=56) patients without prostatic diseases (0.032). IPSS score correlated positively with age, BMI, triglycerides, HDL-cholestrol, and HbA1c. Conclusion: LUTS are frequent in metabolic syndrome patients with or without benign prostatic hyperplasia. In patients with all five components of MetS there was an increased prevalence of LUTS. Resulting from this study it is our reccomendation that patients with MetS need follow up/seek advice from an urological specialist as well.
Authors and Affiliations
Florin Rusu, Emilia Rusu, Gabriela Radulian, Georgiana Enache, Mariana Jinga, Viorel Jinga, Dan Mischianu
Keywords
Related Articles
- EP ID EP102677
- DOI -
- Views 147
- Downloads 0
HYPOGONADISM IN METABOLIC SYNDROME PATIENTS
Introduction. Previous studies have shown a high prevalence of low levels of the endogenous sexual hormones in patients with metabolic syndrome (MetS). The aim of this study was to analyze the prevalence of hypogonadism...
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITION – A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucose homeostasis is maintained by the balanced actions of glucose absorption, gluconeogenesis, glycogenolysis, glucose consumption, glucose excretion and glucose reabsorption. The human kidney is involved in glucose r...
HIGHLIGHTS FROM THE 47TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
THE ASSOCIATION BETWEEN ADIPONECTIN, LEPTIN, PROINFLAMMATORY MARKERS AND METABOLIC SYNDROME IN OBESE, NONDIABETIC SUBJECTS
The aim of this study was to evaluate the association between adipokines (adiponectin and leptin), inflammatory markers, insulin resistance and metabolic syndrome in obese, non-diabetic subjects. Methods: Thirty three ob...
VITAMIN D DEFICIENCY EFFECTS UPON DIABETES MELLITUS AND ITS CARDIOVASCULAR AND RENAL CHRONIC COMPLICATIONS
Vitamin D was proved to have multiple non-skeletal actions, its receptor being expressed by almost every tissue, consequently proper levels being necessary for their optimal functioning. Although biologically inactive, 2...